摘要
Abstract
OBJECTIVE: To observe therapeutic efficacy and safety of alprostadil versus dipyridamole in the treatment of type 2 diabetic nephropathy.METHODS: 64 patients with type 2 diabetes complicating with diabetic nephropathy were randomly divided into group A(n=34) and group B(n=30).After the targets of blood glucose and blood pressure control were achieved, group A were treated with alprostadil while group B with dipyridamole.Before and 14 days after treatment, 24-hour urine protein (24 h UP) , serum creatinine (Scr) , blood urea nitorgen (BUN) , prothrombin time (PT) , activated partial thromboplastin time (APTT), plasma fibrinogen (FIB) and D-dimer (D-D) were detected.Drug adverse reactions were observed.RESULTS: 24 h UP, Scr, BUN, FIB, D-D of 2 groups after treatment were lower than those before treatment (P＜0.05).There was no significant difference in PT and APTT before and after treatment (P＞0.05).After treatment, 24 h UP and FIB of group A were lower than those of group B, there was significant difference (P＜0.05).There was no statistical difference in Scr, BUN and D-D between group A and B.No serious adverse drug reaction was found in 2 groups.CONCLUSION: Both alprostadil and dipyridamole can improve kidney function, and reduce urine protein, plasma fibrinogen and D-D in patients with diabetic nephropathy without serious adverse drug reaction.Alprostadil decreased 24 h UP、 FIB is better than dipyridamole.关键词
前列地尔/双嘧达莫/2型糖尿病肾病Key words
Alprostadil/ Dipyridamole/ Type 2 diabetic nephropathy分类
医药卫生
